Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
Filomena RussoMarco GalluzzoLuca StingeniSeverino PersechinoLeonardo ZichichiAndrea ContiClaudia GiofrèValentina DiniMartina VispiLaura AtzoriAngelo CattaneoAurora ParodiFederico BardazziGiuseppe StincoPaolo DapavoGiampiero GirolomoniMaria Letizia MusumeciManuela PapiniMarina VenturiniStefano DastoliSergio Di NuzzoMaria-Concetta FargnoliGianluca PagnanelliNicoletta BernardiniDaniele Mario GambiniPiergiorgio MalagoliCarlo MazzatentaKetty PerisIris ZalaudekGabriella FabbrociniFrancesco LoconsoleCamilla VassalloLucia PietroleonardoFrancesca PrignanoChiara FranchiAnna Maria OffidaniClaudio BonifatiVito Di LerniaGiovanni GiganteMarta Silvia BartezaghiMatteo FranchiPaola UrsoleoElisabetta AloisiPublished in: Clinical, cosmetic and investigational dermatology (2023)
In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.